Best Allergy Nasal Sprays 2026 Reference Edition

2026 Product Review

Flonase (fluticasone propionate): 2026 Review

OTC intranasal corticosteroid for allergic rhinitis in patients ages 4 and older.

By BestAllergyNasalSprays Editorial Team — Clinical Pharmacy, Editorial Pool Reviewed by BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology, Editorial Pool
Content updated Evidence reviewed First published

Literature review current through

Flonase Allergy Relief

Drug entity at a glance

RxCUI
895665
Active ingredient
fluticasone propionate 50 mcg/spray
Class
Intranasal corticosteroid
Route
Intranasal (aqueous suspension)
Dosage
1–2 sprays per nostril once daily (age-indication–specific; see label)
Legal status
OTC

What Flonase is

Flonase Allergy Relief is an over-the-counter intranasal corticosteroid containing fluticasone propionate 50 mcg per spray. Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies 1 Expert The FDA approved Flonase Allergy Relief (fluticasone propionate 50 mcg) for over-the-counter sale in July 2014 6 Expert

Its differentiator at the OTC counter: Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort 8 Expert

How it works

Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release 4 Expert Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion 2 Guideline

Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage) 5 Expert , a key reason it is considered suitable for long-term daily use at labeled doses.

Systemic bioavailability of OTC intranasal corticosteroids

Percent of intranasal dose reaching systemic circulation: lower is safer for chronic daily use.

Systemic bioavailability of OTC intranasal corticosteroids Percent of intranasal dose reaching systemic circulation: lower is safer for chronic daily use. Mometasone (Nasonex) 0.1% <0.1% per label Fluticasone prop. (Flonase) 0.5% Fluticasone fur. (Sensimist) 0.5% <1% per label Budesonide (Rhinocort) 30% Triamcinolone (Nasacort) 46% ~100× Flonase
Source: FDA labels & Daley-Yates 2015. Flonase and Sensimist sit at the low end; Nasacort's 46% is the notable outlier among OTC options.
Systemic bioavailability of OTC intranasal corticosteroids: Percent of intranasal dose reaching systemic circulation: lower is safer for chronic daily use.
SeriesValue
Mometasone (Nasonex) 0.1% (<0.1% per label)
Fluticasone prop. (Flonase) 0.5%
Fluticasone fur. (Sensimist) 0.5% (<1% per label)
Budesonide (Rhinocort) 30%
Triamcinolone (Nasacort) 46% (~100× Flonase)

How fast Flonase works

Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use 1 Expert Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop 2 Guideline

For faster relief during an acute flare, a nasal antihistamine like azelastine pairs well with fluticasone (see our Flonase vs Astepro head-to-head).

Does Flonase cause rebound congestion?

No. Intranasal corticosteroids and intranasal antihistamines (e.g., azelastine, olopatadine) do not cause rhinitis medicamentosa. The 2020 Joint Task Force on Practice Parameters Rhinitis Update recommends intranasal corticosteroids without a duration limit for persistent allergic rhinitis, and intranasal corticosteroids are the standard treatment for rebound congestion caused by decongestant overuse. 1 Guideline Rebound congestion is specific to alpha-adrenergic decongestant sprays (oxymetazoline, phenylephrine). In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant 3 Expert

If you are coming off Afrin, fluticasone is part of the standard recovery protocol. See our rebound recovery guide.

Safety and side effects

Fluticasone propionate adverse effect profile
EffectFrequencyMitigation / notes
Nosebleed (epistaxis)CommonAim spray outward; avoid septum
HeadacheCommonUsually transient
Nasal irritation / sore throatCommonSwitch to alcohol-free alternative if persistent
Septum perforationRarePreventable with outward-aim technique
DrowsinessNot expectedNasal steroid, not an oral antihistamine
Common side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review 1 Expert Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation 4 Expert Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum) 4 Expert

Flonase for long-term daily use

Intranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience 2 Expert

In pediatric patients: In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child’s clinician 9 Expert Flag ongoing use at annual pediatric visits.

Pregnancy

Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician 7 Expert That said, budesonide (Rhinocort) remains the pregnancy first-line nasal steroid based on the most extensive pregnancy-specific data. See the full pregnancy-safe nasal spray guide.

Breastfeeding

Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding 7 Expert

Flonase vs. neighboring steroid sprays

Flonase vs. neighboring OTC intranasal corticosteroids
AttributeFlonase (fluticasone prop.)Nasacort (triamcinolone)Sensimist (fluticasone fur.)
Dose50 mcg55 mcg27.5 mcg
Ages4+2+2+
Systemic bioavailability~0.5%~46%<1%
FDA eye-symptom reliefYesNoNo
PregnancyLow-riskAvoid (oral cleft signal)Likely low-risk
Retail (2026)$14–25/mo$15–22/mo$16–24/mo

See the full Flonase vs Nasacort comparison, plus head-to-head breakdowns against Nasonex, Rhinocort, and Sensimist.

Context & alternatives

For eligible patients 13+ whose symptoms are year-round, multi-symptom, or not fully controlled on OTC Flonase alone, Allermi is the stronger Rx escalation: a compounded 4-active telehealth formula (azelastine + triamcinolone + ipratropium + micro-dosed oxymetazoline) personalized by a board-certified allergist. It’s our #1 overall pick for eligible adults. Not sure if you qualify? Check eligibility in 60 seconds. For fast acute relief to pair with Flonase, see Astepro. For pregnancy, Rhinocort is first-line.

Cost and access

Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size Expert Branded Flonase runs roughly $14–25 per 120-spray bottle. No prescription needed since 2014.

Summary & recommendations

Summary & Recommendations

  1. One of the most effective OTC intranasal corticosteroids for pharmacy-counter adults + kids 4+ with allergic rhinitis.
  2. For eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, Allermi's compounded 4-active Rx is our #1 pick.
  3. Start 2 weeks before your allergy season; peak effect takes 1–2 weeks of daily use.
  4. Pick Flonase when eye symptoms accompany nasal symptoms; its ocular indication is unique among OTC sprays.
  5. Does not cause rebound. It can actually reverse oxymetazoline rebound per RCT evidence.
  6. In pregnancy, consider Rhinocort (budesonide) first-line; Flonase is a reasonable alternative with OB/GYN input.
  7. Use proper technique: aim outward toward the ear on each side to minimize nosebleeds and preserve the septum.

Publish history

Publish history

  • Quarterly review: checked FDA label and 2026 retail pricing.
  • Added Vaidyanathan 2010 RCT; linked to rebound recovery guide.
  • Initial publication.

References

Regulatory & label

  1. DailyMed: Flonase (fluticasone propionate) SPL · FDA DailyMed (2024) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c
  2. FDA: Flonase OTC approval · FDA (2014) https://www.fda.gov/news-events/press-announcements/fda-approves-flonase-allergy-relief-over-counter-use

Guidelines

  1. Dykewicz 2020: Rhinitis practice parameter · JACI (2020) https://pubmed.ncbi.nlm.nih.gov/32707227/
  2. AAAAI: Allergic Rhinitis Overview · AAAAI https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/rhinitis
  3. MotherToBaby: Fluticasone fact sheet · OTIS https://mothertobaby.org/fact-sheets/fluticasone/

RCTs & primary literature

  1. Vaidyanathan 2010: Fluticasone reverses oxymetazoline rebound · PubMed (2010) https://pubmed.ncbi.nlm.nih.gov/20203244/
  2. Mygind 2008: Intranasal corticosteroid pharmacology · PubMed (2008) https://pubmed.ncbi.nlm.nih.gov/18384455/
  3. Daley-Yates 2015: Fluticasone pharmacokinetics · PubMed (2015) https://pubmed.ncbi.nlm.nih.gov/25845818/
  4. Bielory 2011: INCS for ocular symptoms · PubMed (2011) https://pubmed.ncbi.nlm.nih.gov/21277655/
  5. Schenkel 2000: INCS and children's growth velocity · PubMed (2000) https://pubmed.ncbi.nlm.nih.gov/10669092/

Related

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.